Abstract B071: Preclinical Evaluation of Tumor Treating Fields (TTFields) Applied with KRAS Inhibitors in Pancreatic Ductal Adenocarcinoma Models
Pancreatic ductal adenocarcinoma (PDAC) remains among the most lethal malignancies, with limited survival despite advances in systemic therapy. Activating KRAS mutations, present in approximately 90% of PDACs, contribute to tumor progression in part through regulation of c-Myc. Tumor Treating Fields (TTFields) therap...